AALGX
Price
$31.69
Change
+$0.04 (+0.13%)
Updated
Jul 2 closing price
Net Assets
2.5B
CWICX
Price
$80.52
Change
-$0.06 (-0.07%)
Updated
Jul 2 closing price
Net Assets
159.53B
Interact to see
Advertisement

AALGX vs CWICX

AALGX vs CWICX Comparison Chart in %
View a ticker or compare two or three
VS
AALGX vs. CWICX commentary
Jul 06, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is AALGX is a StrongBuy and CWICX is a Buy.

Interact to see
Advertisement
FUNDAMENTALS
Fundamentals
CWICX has more cash in the bank: 160B vs. AALGX (2.5B). AALGX pays higher dividends than CWICX: AALGX (1.15) vs CWICX (0.66). AALGX was incepted earlier than CWICX: AALGX (39 years) vs CWICX (24 years). CWICX (1.52) is less costly to investors than AALGX (0.95). AALGX is a more actively managed with annual turnover of: 62.00 vs. CWICX (44.00). CWICX has a lower initial minimum investment than AALGX: CWICX (250) vs AALGX (2000). CWICX annual gain was more profitable for investors over the last year : 14.79 vs. AALGX (10.25). CWICX return over 5 years is better than : 30.00 vs. AALGX (8.22).
AALGXCWICXAALGX / CWICX
Total Expense Ratio0.951.5263%
Annual Report Gross Expense Ratio0.951.5263%
Fund Existence39 years24 years-
Gain YTD10.30313.75875%
Front Load5%N/A-
Min. Initial Investment2000250800%
Min. Initial Investment IRAN/AN/A-
Net Assets2.5B160B2%
Annual Yield % from dividends1.150.66176%
Returns for 1 year10.2514.7969%
Returns for 3 years30.6144.8668%
Returns for 5 years8.2230.0027%
Returns for 10 years43.93104.7042%
View a ticker or compare two or three
Interact to see
Advertisement
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
FTDZX213.595.41
+2.60%
Franklin Biotechnology Discovery Adv
MUOSX35.54-0.02
-0.06%
Morgan Stanley Instl US Core R6
PMJAX13.27-0.07
-0.52%
PIMCO RAE US Small A
DFCEX33.87-0.42
-1.22%
DFA Emerging Markets Core Equity 2 I
DSMDX24.11-0.64
-2.59%
Driehaus Small/Mid Cap Growth